June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
micro-RNA-125 attenuates retinal inflammation to preserve vascular integrity in a rat model of oxygen-induced retinopathy
Author Affiliations & Notes
  • Maëlle Wirth
    Universite de Montreal, Montreal, Quebec, Canada
    Hopital Maisonneuve-Rosemont Centre de Recherche, Montreal, Quebec, Canada
  • michel desjarlais
    Hopital Maisonneuve-Rosemont Centre de Recherche, Montreal, Quebec, Canada
  • Isabelle Lahaie
    Hopital Maisonneuve-Rosemont Centre de Recherche, Montreal, Quebec, Canada
  • Sylvain Chemtob
    Universite de Montreal, Montreal, Quebec, Canada
    Hopital Maisonneuve-Rosemont Centre de Recherche, Montreal, Quebec, Canada
  • Footnotes
    Commercial Relationships   Maëlle Wirth None; michel desjarlais None; Isabelle Lahaie None; Sylvain Chemtob None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 2119 – F0135. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maëlle Wirth, michel desjarlais, Isabelle Lahaie, Sylvain Chemtob; micro-RNA-125 attenuates retinal inflammation to preserve vascular integrity in a rat model of oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2022;63(7):2119 – F0135.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose :
Retinal inflammation is associated with vascular degeneration in oxygen-induced-retinopathy (OIR). micro-RNAs (miRs) have been identified as key regulators of genes expression. miR-125 is reported as strongly expressed in the retina, implicated in retinal development and in inflammatory processes. This study aimed to investigate the potential anti-inflammatory properties of miR-125 in a rat model of OIR.

Methods : qRT-PCR and western blot were performed to evaluate the expression of miR-125 and inflammatory cytokines. In vitro: miR-125 function was investigated using a miR-125 mimic on activated microglial cells (SIM-A9) by hyperoxia or LPS. The angiogenic effects were analyzed by Matrigel assay and qRT-PCR. In vivo: OIR rat pups were intravitreally injected with miR-125 mimic (10 nmol/kg) or a control-miR at P5 during the cycling OIR model. Retinal tissues were collected at P10 and P14 and the vascular density was analysed by retinal lectin-immunostaining. Apoptosis was analyzed in vitro and in vivo.

Results : miR-125 expression is significantly reduced in the retina of OIR rats compared to control rats, and in SIM-A9 subjected to hyperoxia or LPS. This is correlated with an upregulation of key proinflammatory cytokines including TNF-a, IL-6 and IL-16. Interestingly, we found a significant decrease of TNF-a, IL-6 and IL-16 expression, associated with decreased apoptosis in SIM-A9 transfected with miR-125 before hyperoxic or LPS treatment. Retinal endothelial cells (HRMEC) exposed with the culture medium of SIM-A9 pre-subjected to hyperoxia display a decrease in their angiogenic capacity associated with an increase of apoptosis. Interestingly, overexpression of miR-125 in SIM-A9 reverses the deleterious effects of hyperoxia on their secretome to rescue vasculogenic function of HRMEC. In vivo, OIR rat pups intravitreally supplemented with miR-125 mimic display a significantly decrease of TNF-a, IL-6, IL-16 and activated Caspase-3, associated with lower vasoobliteration area compared to the miR-control group at P10 and P14.

Conclusions : This study suggests that miR-125 acts as an inflammatory and apoptotic suppressor of activated-microglial cells protecting microvascular density during OIR. miR-125-based therapy could potentially constitute a novel anti-inflammatory therapeutic strategy to limit vascular degeneration in the initial step of ischemic retinopathies.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×